# PeptideScanner evidence objects: Pegcetacoplan

Every published version of the records placed with Pegcetacoplan, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json. Selected public evidence only; not medical advice.

- Objects: 51
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct02264639-pegcetacoplan-v1"></a>

## ClinicalTrials.gov record NCT02264639

> PeptideScanner retained ClinicalTrials.gov record NCT02264639 at 2026-11-16T01:37:14.654Z. Its registry update date was 2021-01-08, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

- Evidence object: `story:clinicaltrials-gov-nct02264639-pegcetacoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-01-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02264639-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct02264639-pegcetacoplan-v1
- Content SHA-256: `ef2bf2fa02e5652f591db752dc549acb696a2ad3e459e9f97798ab67fe9a0f9b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02264639 ([`ctg-observation-nct02264639-2021-01-08-f1f8026b6b7c`](#source-ctg-observation-nct02264639-2021-01-08-f1f8026b6b7c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02264639 at 2026-11-16T01:37:14.654Z. Its registry update date was 2021-01-08, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct02264639-2021-01-08-f1f8026b6b7c`](#source-ctg-observation-nct02264639-2021-01-08-f1f8026b6b7c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02264639 at 2026-11-16T01:37:14.654Z. Its registry update date was 2021-01-08, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct02264639-2021-01-08-f1f8026b6b7c`](#source-ctg-observation-nct02264639-2021-01-08-f1f8026b6b7c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02264639-2021-01-08-f1f8026b6b7c`](#source-ctg-observation-nct02264639-2021-01-08-f1f8026b6b7c))

### Sources

<a id="source-ctg-observation-nct02264639-2021-01-08-f1f8026b6b7c"></a>
- **ClinicalTrials.gov record NCT02264639 · retained source version 2021-01-08:f1f8026b6b7c8dcebf55ab5dbe3f7ff35fa29f87d64b2b2ecf48bae04cbebe85** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02264639) (`ctg-observation-nct02264639-2021-01-08-f1f8026b6b7c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02264639." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct02264639-pegcetacoplan-v1 SHA-256: ef2bf2fa02e5652f591db752dc549acb696a2ad3e459e9f97798ab67fe9a0f9b.

---

<a id="clinicaltrials-gov-nct02461771-pegcetacoplan-v1"></a>

## ClinicalTrials.gov record NCT02461771

> PeptideScanner retained ClinicalTrials.gov record NCT02461771 at 2026-11-16T01:37:14.654Z. Its registry update date was 2020-10-06, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

- Evidence object: `story:clinicaltrials-gov-nct02461771-pegcetacoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-10-06
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02461771-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct02461771-pegcetacoplan-v1
- Content SHA-256: `02ba7b97ba431e25361b07d9332d51f1ed572ffa5d974b0f202390d924532b6b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02461771 ([`ctg-observation-nct02461771-2020-10-06-1c44a444374d`](#source-ctg-observation-nct02461771-2020-10-06-1c44a444374d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02461771 at 2026-11-16T01:37:14.654Z. Its registry update date was 2020-10-06, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct02461771-2020-10-06-1c44a444374d`](#source-ctg-observation-nct02461771-2020-10-06-1c44a444374d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02461771 at 2026-11-16T01:37:14.654Z. Its registry update date was 2020-10-06, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct02461771-2020-10-06-1c44a444374d`](#source-ctg-observation-nct02461771-2020-10-06-1c44a444374d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02461771-2020-10-06-1c44a444374d`](#source-ctg-observation-nct02461771-2020-10-06-1c44a444374d))

### Sources

<a id="source-ctg-observation-nct02461771-2020-10-06-1c44a444374d"></a>
- **ClinicalTrials.gov record NCT02461771 · retained source version 2020-10-06:1c44a444374d941a8d65c33d9ac996ad0c04509544f7e978bf5a824ecaf2eff1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02461771) (`ctg-observation-nct02461771-2020-10-06-1c44a444374d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02461771." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct02461771-pegcetacoplan-v1 SHA-256: 02ba7b97ba431e25361b07d9332d51f1ed572ffa5d974b0f202390d924532b6b.

---

<a id="clinicaltrials-gov-nct02503332-pegcetacoplan-v1"></a>

## ClinicalTrials.gov record NCT02503332

> PeptideScanner retained ClinicalTrials.gov record NCT02503332 at 2026-11-16T01:37:14.654Z. Its registry update date was 2020-10-06, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

- Evidence object: `story:clinicaltrials-gov-nct02503332-pegcetacoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-10-06
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02503332-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct02503332-pegcetacoplan-v1
- Content SHA-256: `771bcc3a2c1743358ecac7dd98a1fedf8de3409d4993cc3901f64e8757a2a03b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02503332 ([`ctg-observation-nct02503332-2020-10-06-f5a1a1c1cb6e`](#source-ctg-observation-nct02503332-2020-10-06-f5a1a1c1cb6e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02503332 at 2026-11-16T01:37:14.654Z. Its registry update date was 2020-10-06, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct02503332-2020-10-06-f5a1a1c1cb6e`](#source-ctg-observation-nct02503332-2020-10-06-f5a1a1c1cb6e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02503332 at 2026-11-16T01:37:14.654Z. Its registry update date was 2020-10-06, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct02503332-2020-10-06-f5a1a1c1cb6e`](#source-ctg-observation-nct02503332-2020-10-06-f5a1a1c1cb6e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02503332-2020-10-06-f5a1a1c1cb6e`](#source-ctg-observation-nct02503332-2020-10-06-f5a1a1c1cb6e))

### Sources

<a id="source-ctg-observation-nct02503332-2020-10-06-f5a1a1c1cb6e"></a>
- **ClinicalTrials.gov record NCT02503332 · retained source version 2020-10-06:f5a1a1c1cb6ea49db85723bf92c91bf3a22f8f13f039ec53dda7b71fb6764d1b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02503332) (`ctg-observation-nct02503332-2020-10-06-f5a1a1c1cb6e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02503332." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct02503332-pegcetacoplan-v1 SHA-256: 771bcc3a2c1743358ecac7dd98a1fedf8de3409d4993cc3901f64e8757a2a03b.

---

<a id="clinicaltrials-gov-nct02588833-pegcetacoplan-v1"></a>

## ClinicalTrials.gov record NCT02588833

> PeptideScanner retained ClinicalTrials.gov record NCT02588833 at 2026-11-16T01:37:14.654Z. Its registry update date was 2021-01-11, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

- Evidence object: `story:clinicaltrials-gov-nct02588833-pegcetacoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-01-11
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02588833-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct02588833-pegcetacoplan-v1
- Content SHA-256: `d6bb6b8299e0c697d7e2412317c70b9d7d1ce95b94990e496c30aa85edf7626e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02588833 ([`ctg-observation-nct02588833-2021-01-11-aa8fa7d43361`](#source-ctg-observation-nct02588833-2021-01-11-aa8fa7d43361))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02588833 at 2026-11-16T01:37:14.654Z. Its registry update date was 2021-01-11, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct02588833-2021-01-11-aa8fa7d43361`](#source-ctg-observation-nct02588833-2021-01-11-aa8fa7d43361))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02588833 at 2026-11-16T01:37:14.654Z. Its registry update date was 2021-01-11, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct02588833-2021-01-11-aa8fa7d43361`](#source-ctg-observation-nct02588833-2021-01-11-aa8fa7d43361))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02588833-2021-01-11-aa8fa7d43361`](#source-ctg-observation-nct02588833-2021-01-11-aa8fa7d43361))

### Sources

<a id="source-ctg-observation-nct02588833-2021-01-11-aa8fa7d43361"></a>
- **ClinicalTrials.gov record NCT02588833 · retained source version 2021-01-11:aa8fa7d43361481ff6b021733fc32ee9039c85f9c1f1b59a59760ca795dacf89** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02588833) (`ctg-observation-nct02588833-2021-01-11-aa8fa7d43361`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02588833." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct02588833-pegcetacoplan-v1 SHA-256: d6bb6b8299e0c697d7e2412317c70b9d7d1ce95b94990e496c30aa85edf7626e.

---

<a id="clinicaltrials-gov-nct03500549-pegcetacoplan-v1"></a>

## ClinicalTrials.gov record NCT03500549

> PeptideScanner retained ClinicalTrials.gov record NCT03500549 at 2026-11-16T01:37:14.654Z. Its registry update date was 2022-03-25, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

- Evidence object: `story:clinicaltrials-gov-nct03500549-pegcetacoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-03-25
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03500549-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct03500549-pegcetacoplan-v1
- Content SHA-256: `29b8343b4d1e7e4df2897971670328cf11a04d1077f4bc360d86f466878461bb`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03500549 ([`ctg-observation-nct03500549-2022-03-25-b9f45a29a7a5`](#source-ctg-observation-nct03500549-2022-03-25-b9f45a29a7a5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03500549 at 2026-11-16T01:37:14.654Z. Its registry update date was 2022-03-25, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct03500549-2022-03-25-b9f45a29a7a5`](#source-ctg-observation-nct03500549-2022-03-25-b9f45a29a7a5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03500549 at 2026-11-16T01:37:14.654Z. Its registry update date was 2022-03-25, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct03500549-2022-03-25-b9f45a29a7a5`](#source-ctg-observation-nct03500549-2022-03-25-b9f45a29a7a5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03500549-2022-03-25-b9f45a29a7a5`](#source-ctg-observation-nct03500549-2022-03-25-b9f45a29a7a5))

### Sources

<a id="source-ctg-observation-nct03500549-2022-03-25-b9f45a29a7a5"></a>
- **ClinicalTrials.gov record NCT03500549 · retained source version 2022-03-25:b9f45a29a7a571b2841b5cb64fd6c8f6c21ec78e50300861ed5294c8cf087c5e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03500549) (`ctg-observation-nct03500549-2022-03-25-b9f45a29a7a5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03500549." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct03500549-pegcetacoplan-v1 SHA-256: 29b8343b4d1e7e4df2897971670328cf11a04d1077f4bc360d86f466878461bb.

---

<a id="clinicaltrials-gov-nct03525613-pegcetacoplan-v1"></a>

## ClinicalTrials.gov record NCT03525613

> PeptideScanner retained ClinicalTrials.gov record NCT03525613 at 2026-11-16T01:37:14.654Z. Its registry update date was 2023-07-06, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

- Evidence object: `story:clinicaltrials-gov-nct03525613-pegcetacoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-07-06
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03525613-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct03525613-pegcetacoplan-v1
- Content SHA-256: `114f47c4a4660178d1aaa8ca2d00c8b6b3ba599e5871170876d0986b2ed4e03f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03525613 ([`ctg-observation-nct03525613-2023-07-06-1450af6cb070`](#source-ctg-observation-nct03525613-2023-07-06-1450af6cb070))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03525613 at 2026-11-16T01:37:14.654Z. Its registry update date was 2023-07-06, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct03525613-2023-07-06-1450af6cb070`](#source-ctg-observation-nct03525613-2023-07-06-1450af6cb070))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03525613 at 2026-11-16T01:37:14.654Z. Its registry update date was 2023-07-06, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct03525613-2023-07-06-1450af6cb070`](#source-ctg-observation-nct03525613-2023-07-06-1450af6cb070))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03525613-2023-07-06-1450af6cb070`](#source-ctg-observation-nct03525613-2023-07-06-1450af6cb070))

### Sources

<a id="source-ctg-observation-nct03525613-2023-07-06-1450af6cb070"></a>
- **ClinicalTrials.gov record NCT03525613 · retained source version 2023-07-06:1450af6cb0701ce22bc555ef745d36005e86aee77451fb6be5602fee7fb67c19** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03525613) (`ctg-observation-nct03525613-2023-07-06-1450af6cb070`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03525613." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct03525613-pegcetacoplan-v1 SHA-256: 114f47c4a4660178d1aaa8ca2d00c8b6b3ba599e5871170876d0986b2ed4e03f.

---

<a id="clinicaltrials-gov-nct03531255-pegcetacoplan-v1"></a>

## ClinicalTrials.gov record NCT03531255

> PeptideScanner retained ClinicalTrials.gov record NCT03531255 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

- Evidence object: `story:clinicaltrials-gov-nct03531255-pegcetacoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03531255-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct03531255-pegcetacoplan-v1
- Content SHA-256: `3c66e95d04f0ea69897bf119c61709744508e9785130a12f245931b77a67aa41`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03531255 ([`ctg-observation-nct03531255-2026-11-10-6e0d7b80e1fc`](#source-ctg-observation-nct03531255-2026-11-10-6e0d7b80e1fc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03531255 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct03531255-2026-11-10-6e0d7b80e1fc`](#source-ctg-observation-nct03531255-2026-11-10-6e0d7b80e1fc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03531255 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct03531255-2026-11-10-6e0d7b80e1fc`](#source-ctg-observation-nct03531255-2026-11-10-6e0d7b80e1fc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03531255-2026-11-10-6e0d7b80e1fc`](#source-ctg-observation-nct03531255-2026-11-10-6e0d7b80e1fc))

### Sources

<a id="source-ctg-observation-nct03531255-2026-11-10-6e0d7b80e1fc"></a>
- **ClinicalTrials.gov record NCT03531255 · retained source version 2026-11-10:6e0d7b80e1fc3b63527a789249639f01019af7d291584a303379c9b2d36ea7a7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03531255) (`ctg-observation-nct03531255-2026-11-10-6e0d7b80e1fc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03531255." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct03531255-pegcetacoplan-v1 SHA-256: 3c66e95d04f0ea69897bf119c61709744508e9785130a12f245931b77a67aa41.

---

<a id="clinicaltrials-gov-nct03593200-pegcetacoplan-v1"></a>

## ClinicalTrials.gov record NCT03593200

> PeptideScanner retained ClinicalTrials.gov record NCT03593200 at 2026-11-16T01:37:14.654Z. Its registry update date was 2020-12-22, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

- Evidence object: `story:clinicaltrials-gov-nct03593200-pegcetacoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-12-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03593200-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct03593200-pegcetacoplan-v1
- Content SHA-256: `9a41f494327bebdfd763f44a1139bd3fd347940ec6ce064a90a24aee29d01934`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03593200 ([`ctg-observation-nct03593200-2020-12-22-703e47ce2650`](#source-ctg-observation-nct03593200-2020-12-22-703e47ce2650))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03593200 at 2026-11-16T01:37:14.654Z. Its registry update date was 2020-12-22, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct03593200-2020-12-22-703e47ce2650`](#source-ctg-observation-nct03593200-2020-12-22-703e47ce2650))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03593200 at 2026-11-16T01:37:14.654Z. Its registry update date was 2020-12-22, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct03593200-2020-12-22-703e47ce2650`](#source-ctg-observation-nct03593200-2020-12-22-703e47ce2650))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03593200-2020-12-22-703e47ce2650`](#source-ctg-observation-nct03593200-2020-12-22-703e47ce2650))

### Sources

<a id="source-ctg-observation-nct03593200-2020-12-22-703e47ce2650"></a>
- **ClinicalTrials.gov record NCT03593200 · retained source version 2020-12-22:703e47ce2650a77c319a4220ef718d6968f3ba6e787b0af7c3d4491b59882b35** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03593200) (`ctg-observation-nct03593200-2020-12-22-703e47ce2650`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03593200." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct03593200-pegcetacoplan-v1 SHA-256: 9a41f494327bebdfd763f44a1139bd3fd347940ec6ce064a90a24aee29d01934.

---

<a id="clinicaltrials-gov-nct04572854-pegcetacoplan-v1"></a>

## ClinicalTrials.gov record NCT04572854

> PeptideScanner retained ClinicalTrials.gov record NCT04572854 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

- Evidence object: `story:clinicaltrials-gov-nct04572854-pegcetacoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04572854-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct04572854-pegcetacoplan-v1
- Content SHA-256: `6d45dfd45ad199e1b66c08fd7b2ace7515bddcf7443fe615c427eef873c9e1eb`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04572854 ([`ctg-observation-nct04572854-2026-04-21-e899a47aa65b`](#source-ctg-observation-nct04572854-2026-04-21-e899a47aa65b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04572854 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct04572854-2026-04-21-e899a47aa65b`](#source-ctg-observation-nct04572854-2026-04-21-e899a47aa65b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04572854 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct04572854-2026-04-21-e899a47aa65b`](#source-ctg-observation-nct04572854-2026-04-21-e899a47aa65b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04572854-2026-04-21-e899a47aa65b`](#source-ctg-observation-nct04572854-2026-04-21-e899a47aa65b))

### Sources

<a id="source-ctg-observation-nct04572854-2026-04-21-e899a47aa65b"></a>
- **ClinicalTrials.gov record NCT04572854 · retained source version 2026-04-21:e899a47aa65b566b11bd0a84af8b9c353c454b14144b0f082d4fae7f9f86fb6b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04572854) (`ctg-observation-nct04572854-2026-04-21-e899a47aa65b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04572854." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct04572854-pegcetacoplan-v1 SHA-256: 6d45dfd45ad199e1b66c08fd7b2ace7515bddcf7443fe615c427eef873c9e1eb.

---

<a id="clinicaltrials-gov-nct04901936-pegcetacoplan-v1"></a>

## ClinicalTrials.gov record NCT04901936

> PeptideScanner retained ClinicalTrials.gov record NCT04901936 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-06-26, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

- Evidence object: `story:clinicaltrials-gov-nct04901936-pegcetacoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-26
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04901936-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct04901936-pegcetacoplan-v1
- Content SHA-256: `6b6e28405225382208decb6de6516d31ebf9ca181aac6066e3597a802349e090`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04901936 ([`ctg-observation-nct04901936-2026-06-26-95076f766d96`](#source-ctg-observation-nct04901936-2026-06-26-95076f766d96))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04901936 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-06-26, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct04901936-2026-06-26-95076f766d96`](#source-ctg-observation-nct04901936-2026-06-26-95076f766d96))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04901936 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-06-26, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct04901936-2026-06-26-95076f766d96`](#source-ctg-observation-nct04901936-2026-06-26-95076f766d96))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04901936-2026-06-26-95076f766d96`](#source-ctg-observation-nct04901936-2026-06-26-95076f766d96))

### Sources

<a id="source-ctg-observation-nct04901936-2026-06-26-95076f766d96"></a>
- **ClinicalTrials.gov record NCT04901936 · retained source version 2026-06-26:95076f766d96ae0a5fcf59eccd41aa8131b49c19165a390be866850ee635365c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04901936) (`ctg-observation-nct04901936-2026-06-26-95076f766d96`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04901936." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct04901936-pegcetacoplan-v1 SHA-256: 6b6e28405225382208decb6de6516d31ebf9ca181aac6066e3597a802349e090.

---

<a id="clinicaltrials-gov-nct04919629-pegcetacoplan-v1"></a>

## ClinicalTrials.gov record NCT04919629

> PeptideScanner retained ClinicalTrials.gov record NCT04919629 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

- Evidence object: `story:clinicaltrials-gov-nct04919629-pegcetacoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-23
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04919629-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct04919629-pegcetacoplan-v1
- Content SHA-256: `37fc67ff576e1fea51e71b4fd9473ddaa4418a9f0cb41cf45d4e39822c8d9bc8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04919629 ([`ctg-observation-nct04919629-2026-03-23-6d8f940fb161`](#source-ctg-observation-nct04919629-2026-03-23-6d8f940fb161))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04919629 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct04919629-2026-03-23-6d8f940fb161`](#source-ctg-observation-nct04919629-2026-03-23-6d8f940fb161))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04919629 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct04919629-2026-03-23-6d8f940fb161`](#source-ctg-observation-nct04919629-2026-03-23-6d8f940fb161))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04919629-2026-03-23-6d8f940fb161`](#source-ctg-observation-nct04919629-2026-03-23-6d8f940fb161))

### Sources

<a id="source-ctg-observation-nct04919629-2026-03-23-6d8f940fb161"></a>
- **ClinicalTrials.gov record NCT04919629 · retained source version 2026-03-23:6d8f940fb16159da2468c2865cce76decdd173456c96e2f59e3c3b617094dd2d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04919629) (`ctg-observation-nct04919629-2026-03-23-6d8f940fb161`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04919629." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct04919629-pegcetacoplan-v1 SHA-256: 37fc67ff576e1fea51e71b4fd9473ddaa4418a9f0cb41cf45d4e39822c8d9bc8.

---

<a id="clinicaltrials-gov-nct05067127-pegcetacoplan-v1"></a>

## ClinicalTrials.gov record NCT05067127

> PeptideScanner retained ClinicalTrials.gov record NCT05067127 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-01-29, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

- Evidence object: `story:clinicaltrials-gov-nct05067127-pegcetacoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-01-29
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05067127-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct05067127-pegcetacoplan-v1
- Content SHA-256: `f7d0188ab58d7038e8a24622c2bde3ccaaaa721c03576245700931b56639bf22`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05067127 ([`ctg-observation-nct05067127-2026-01-29-a616a2629b0e`](#source-ctg-observation-nct05067127-2026-01-29-a616a2629b0e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05067127 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-01-29, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct05067127-2026-01-29-a616a2629b0e`](#source-ctg-observation-nct05067127-2026-01-29-a616a2629b0e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05067127 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-01-29, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct05067127-2026-01-29-a616a2629b0e`](#source-ctg-observation-nct05067127-2026-01-29-a616a2629b0e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05067127-2026-01-29-a616a2629b0e`](#source-ctg-observation-nct05067127-2026-01-29-a616a2629b0e))

### Sources

<a id="source-ctg-observation-nct05067127-2026-01-29-a616a2629b0e"></a>
- **ClinicalTrials.gov record NCT05067127 · retained source version 2026-01-29:a616a2629b0e524c9af94d3546df63298a6d3cd2c56ab067d5109043c635b7f5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05067127) (`ctg-observation-nct05067127-2026-01-29-a616a2629b0e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05067127." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct05067127-pegcetacoplan-v1 SHA-256: f7d0188ab58d7038e8a24622c2bde3ccaaaa721c03576245700931b56639bf22.

---

<a id="clinicaltrials-gov-nct05096403-pegcetacoplan-v1"></a>

## ClinicalTrials.gov record NCT05096403

> PeptideScanner retained ClinicalTrials.gov record NCT05096403 at 2026-11-16T01:37:14.654Z. Its registry update date was 2025-10-30, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

- Evidence object: `story:clinicaltrials-gov-nct05096403-pegcetacoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-10-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05096403-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct05096403-pegcetacoplan-v1
- Content SHA-256: `7a12595097c998b9cbb978936e714e86a040a61a26725170d05f5d3e243307b3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05096403 ([`ctg-observation-nct05096403-2025-10-30-07b875d0c227`](#source-ctg-observation-nct05096403-2025-10-30-07b875d0c227))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05096403 at 2026-11-16T01:37:14.654Z. Its registry update date was 2025-10-30, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct05096403-2025-10-30-07b875d0c227`](#source-ctg-observation-nct05096403-2025-10-30-07b875d0c227))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05096403 at 2026-11-16T01:37:14.654Z. Its registry update date was 2025-10-30, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct05096403-2025-10-30-07b875d0c227`](#source-ctg-observation-nct05096403-2025-10-30-07b875d0c227))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05096403-2025-10-30-07b875d0c227`](#source-ctg-observation-nct05096403-2025-10-30-07b875d0c227))

### Sources

<a id="source-ctg-observation-nct05096403-2025-10-30-07b875d0c227"></a>
- **ClinicalTrials.gov record NCT05096403 · retained source version 2025-10-30:07b875d0c2276631011abc7d30b2ee556a8c0dc799ecf5a1824ffab7f9ba132c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05096403) (`ctg-observation-nct05096403-2025-10-30-07b875d0c227`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05096403." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct05096403-pegcetacoplan-v1 SHA-256: 7a12595097c998b9cbb978936e714e86a040a61a26725170d05f5d3e243307b3.

---

<a id="clinicaltrials-gov-nct05148299-pegcetacoplan-v1"></a>

## ClinicalTrials.gov record NCT05148299

> PeptideScanner retained ClinicalTrials.gov record NCT05148299 at 2026-11-16T01:37:14.654Z. Its registry update date was 2025-11-28, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

- Evidence object: `story:clinicaltrials-gov-nct05148299-pegcetacoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-11-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05148299-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct05148299-pegcetacoplan-v1
- Content SHA-256: `4786d0b7ff97262c689ffc67d5cbb13d31596973b0afc6ed9cbacdfd8660d4d5`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05148299 ([`ctg-observation-nct05148299-2025-11-28-ff9aa01f2462`](#source-ctg-observation-nct05148299-2025-11-28-ff9aa01f2462))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05148299 at 2026-11-16T01:37:14.654Z. Its registry update date was 2025-11-28, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct05148299-2025-11-28-ff9aa01f2462`](#source-ctg-observation-nct05148299-2025-11-28-ff9aa01f2462))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05148299 at 2026-11-16T01:37:14.654Z. Its registry update date was 2025-11-28, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct05148299-2025-11-28-ff9aa01f2462`](#source-ctg-observation-nct05148299-2025-11-28-ff9aa01f2462))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05148299-2025-11-28-ff9aa01f2462`](#source-ctg-observation-nct05148299-2025-11-28-ff9aa01f2462))

### Sources

<a id="source-ctg-observation-nct05148299-2025-11-28-ff9aa01f2462"></a>
- **ClinicalTrials.gov record NCT05148299 · retained source version 2025-11-28:ff9aa01f246299e80bf155a09135b640ae83e15c67eb5c64a212f330749cd91f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05148299) (`ctg-observation-nct05148299-2025-11-28-ff9aa01f2462`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05148299." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct05148299-pegcetacoplan-v1 SHA-256: 4786d0b7ff97262c689ffc67d5cbb13d31596973b0afc6ed9cbacdfd8660d4d5.

---

<a id="clinicaltrials-gov-nct05776472-pegcetacoplan-v1"></a>

## ClinicalTrials.gov record NCT05776472

> PeptideScanner retained ClinicalTrials.gov record NCT05776472 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

- Evidence object: `story:clinicaltrials-gov-nct05776472-pegcetacoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05776472-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct05776472-pegcetacoplan-v1
- Content SHA-256: `1b0941e206d3876c4e29bc45df635b2c2d3441ed48acfe0b52e07af3299d89ef`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05776472 ([`ctg-observation-nct05776472-2026-09-03-87cb02e69c9b`](#source-ctg-observation-nct05776472-2026-09-03-87cb02e69c9b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05776472 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct05776472-2026-09-03-87cb02e69c9b`](#source-ctg-observation-nct05776472-2026-09-03-87cb02e69c9b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05776472 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct05776472-2026-09-03-87cb02e69c9b`](#source-ctg-observation-nct05776472-2026-09-03-87cb02e69c9b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05776472-2026-09-03-87cb02e69c9b`](#source-ctg-observation-nct05776472-2026-09-03-87cb02e69c9b))

### Sources

<a id="source-ctg-observation-nct05776472-2026-09-03-87cb02e69c9b"></a>
- **ClinicalTrials.gov record NCT05776472 · retained source version 2026-09-03:87cb02e69c9bbd942f1fdab1c80478cb4e60bf709f994114a02e1da60eb1df11** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05776472) (`ctg-observation-nct05776472-2026-09-03-87cb02e69c9b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05776472." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct05776472-pegcetacoplan-v1 SHA-256: 1b0941e206d3876c4e29bc45df635b2c2d3441ed48acfe0b52e07af3299d89ef.

---

<a id="clinicaltrials-gov-nct05809531-pegcetacoplan-v1"></a>

## ClinicalTrials.gov record NCT05809531

> PeptideScanner retained ClinicalTrials.gov record NCT05809531 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-04-02, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

- Evidence object: `story:clinicaltrials-gov-nct05809531-pegcetacoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05809531-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct05809531-pegcetacoplan-v1
- Content SHA-256: `af46d608b9fe9d7bb7f65d54c868c5b5022febc032e7f4a1cf2459dda77a3192`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05809531 ([`ctg-observation-nct05809531-2026-04-02-df2412e6ef35`](#source-ctg-observation-nct05809531-2026-04-02-df2412e6ef35))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05809531 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-04-02, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct05809531-2026-04-02-df2412e6ef35`](#source-ctg-observation-nct05809531-2026-04-02-df2412e6ef35))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05809531 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-04-02, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct05809531-2026-04-02-df2412e6ef35`](#source-ctg-observation-nct05809531-2026-04-02-df2412e6ef35))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05809531-2026-04-02-df2412e6ef35`](#source-ctg-observation-nct05809531-2026-04-02-df2412e6ef35))

### Sources

<a id="source-ctg-observation-nct05809531-2026-04-02-df2412e6ef35"></a>
- **ClinicalTrials.gov record NCT05809531 · retained source version 2026-04-02:df2412e6ef3591f717531f54b4db7fd35408f6f68cf3a547faa6ee9392581ef5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05809531) (`ctg-observation-nct05809531-2026-04-02-df2412e6ef35`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05809531." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct05809531-pegcetacoplan-v1 SHA-256: af46d608b9fe9d7bb7f65d54c868c5b5022febc032e7f4a1cf2459dda77a3192.

---

<a id="clinicaltrials-gov-nct06161584-pegcetacoplan-v1"></a>

## ClinicalTrials.gov record NCT06161584

> PeptideScanner retained ClinicalTrials.gov record NCT06161584 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-06-01, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

- Evidence object: `story:clinicaltrials-gov-nct06161584-pegcetacoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06161584-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct06161584-pegcetacoplan-v1
- Content SHA-256: `234e0401b474fc56887a3762f64081d05e2b7b3eae46d641ee3e875878f1d63f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06161584 ([`ctg-observation-nct06161584-2026-06-01-4e150d3c90a0`](#source-ctg-observation-nct06161584-2026-06-01-4e150d3c90a0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06161584 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-06-01, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct06161584-2026-06-01-4e150d3c90a0`](#source-ctg-observation-nct06161584-2026-06-01-4e150d3c90a0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06161584 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-06-01, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct06161584-2026-06-01-4e150d3c90a0`](#source-ctg-observation-nct06161584-2026-06-01-4e150d3c90a0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06161584-2026-06-01-4e150d3c90a0`](#source-ctg-observation-nct06161584-2026-06-01-4e150d3c90a0))

### Sources

<a id="source-ctg-observation-nct06161584-2026-06-01-4e150d3c90a0"></a>
- **ClinicalTrials.gov record NCT06161584 · retained source version 2026-06-01:4e150d3c90a005ed1838b83e4028a2e535b7fe82589ec51f89843402ed132199** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06161584) (`ctg-observation-nct06161584-2026-06-01-4e150d3c90a0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06161584." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct06161584-pegcetacoplan-v1 SHA-256: 234e0401b474fc56887a3762f64081d05e2b7b3eae46d641ee3e875878f1d63f.

---

<a id="clinicaltrials-gov-nct06722157-pegcetacoplan-v1"></a>

## ClinicalTrials.gov record NCT06722157

> PeptideScanner retained ClinicalTrials.gov record NCT06722157 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

- Evidence object: `story:clinicaltrials-gov-nct06722157-pegcetacoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-12
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06722157-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct06722157-pegcetacoplan-v1
- Content SHA-256: `29436ab220c2699743947d460108356aeb49e1f5312ac6109565d663a3fd49e7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06722157 ([`ctg-observation-nct06722157-2026-11-12-fb4587df0b93`](#source-ctg-observation-nct06722157-2026-11-12-fb4587df0b93))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06722157 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct06722157-2026-11-12-fb4587df0b93`](#source-ctg-observation-nct06722157-2026-11-12-fb4587df0b93))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06722157 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct06722157-2026-11-12-fb4587df0b93`](#source-ctg-observation-nct06722157-2026-11-12-fb4587df0b93))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06722157-2026-11-12-fb4587df0b93`](#source-ctg-observation-nct06722157-2026-11-12-fb4587df0b93))

### Sources

<a id="source-ctg-observation-nct06722157-2026-11-12-fb4587df0b93"></a>
- **ClinicalTrials.gov record NCT06722157 · retained source version 2026-11-12:fb4587df0b9385615bae6081e27243d35e695a4263b82a36a472ea4ee3c35da6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06722157) (`ctg-observation-nct06722157-2026-11-12-fb4587df0b93`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06722157." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct06722157-pegcetacoplan-v1 SHA-256: 29436ab220c2699743947d460108356aeb49e1f5312ac6109565d663a3fd49e7.

---

<a id="clinicaltrials-gov-nct07160179-pegcetacoplan-v1"></a>

## ClinicalTrials.gov record NCT07160179

> PeptideScanner retained ClinicalTrials.gov record NCT07160179 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

- Evidence object: `story:clinicaltrials-gov-nct07160179-pegcetacoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07160179-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct07160179-pegcetacoplan-v1
- Content SHA-256: `272eb2008975f39fc3305cdef46f5d2532fa27dc214b0ba9b2a4046e5d15c975`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07160179 ([`ctg-observation-nct07160179-2026-07-13-24f77aad4ea7`](#source-ctg-observation-nct07160179-2026-07-13-24f77aad4ea7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07160179 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct07160179-2026-07-13-24f77aad4ea7`](#source-ctg-observation-nct07160179-2026-07-13-24f77aad4ea7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07160179 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct07160179-2026-07-13-24f77aad4ea7`](#source-ctg-observation-nct07160179-2026-07-13-24f77aad4ea7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07160179-2026-07-13-24f77aad4ea7`](#source-ctg-observation-nct07160179-2026-07-13-24f77aad4ea7))

### Sources

<a id="source-ctg-observation-nct07160179-2026-07-13-24f77aad4ea7"></a>
- **ClinicalTrials.gov record NCT07160179 · retained source version 2026-07-13:24f77aad4ea724c8ff035edbce0364b6360b8643c1e57c88ce273b56f13dc3fd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07160179) (`ctg-observation-nct07160179-2026-07-13-24f77aad4ea7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07160179." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct07160179-pegcetacoplan-v1 SHA-256: 272eb2008975f39fc3305cdef46f5d2532fa27dc214b0ba9b2a4046e5d15c975.

---

<a id="clinicaltrials-gov-nct07214298-pegcetacoplan-v1"></a>

## ClinicalTrials.gov record NCT07214298

> PeptideScanner retained ClinicalTrials.gov record NCT07214298 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-08-19, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

- Evidence object: `story:clinicaltrials-gov-nct07214298-pegcetacoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-19
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07214298-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct07214298-pegcetacoplan-v1
- Content SHA-256: `f2b24f251b69aabdf0789f1b1406e745fa1a26ea81654f646d62f2704f52d8aa`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07214298 ([`ctg-observation-nct07214298-2026-08-19-f759ea99d715`](#source-ctg-observation-nct07214298-2026-08-19-f759ea99d715))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07214298 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-08-19, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct07214298-2026-08-19-f759ea99d715`](#source-ctg-observation-nct07214298-2026-08-19-f759ea99d715))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07214298 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-08-19, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct07214298-2026-08-19-f759ea99d715`](#source-ctg-observation-nct07214298-2026-08-19-f759ea99d715))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07214298-2026-08-19-f759ea99d715`](#source-ctg-observation-nct07214298-2026-08-19-f759ea99d715))

### Sources

<a id="source-ctg-observation-nct07214298-2026-08-19-f759ea99d715"></a>
- **ClinicalTrials.gov record NCT07214298 · retained source version 2026-08-19:f759ea99d7158d526c8096807a0f7d0f3b57df7fec217e4afbaa5cfed2f27541** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07214298) (`ctg-observation-nct07214298-2026-08-19-f759ea99d715`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07214298." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct07214298-pegcetacoplan-v1 SHA-256: f2b24f251b69aabdf0789f1b1406e745fa1a26ea81654f646d62f2704f52d8aa.

---

<a id="clinicaltrials-gov-nct07495722-pegcetacoplan-v1"></a>

## ClinicalTrials.gov record NCT07495722

> PeptideScanner retained ClinicalTrials.gov record NCT07495722 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-04-29, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

- Evidence object: `story:clinicaltrials-gov-nct07495722-pegcetacoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-29
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07495722-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct07495722-pegcetacoplan-v1
- Content SHA-256: `8ebfd6fbf91ede1d82b3bfca6c6716caa9e824b002d82883b55f216647468f3a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07495722 ([`ctg-observation-nct07495722-2026-04-29-4571145eb4ea`](#source-ctg-observation-nct07495722-2026-04-29-4571145eb4ea))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07495722 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-04-29, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct07495722-2026-04-29-4571145eb4ea`](#source-ctg-observation-nct07495722-2026-04-29-4571145eb4ea))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07495722 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-04-29, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct07495722-2026-04-29-4571145eb4ea`](#source-ctg-observation-nct07495722-2026-04-29-4571145eb4ea))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07495722-2026-04-29-4571145eb4ea`](#source-ctg-observation-nct07495722-2026-04-29-4571145eb4ea))

### Sources

<a id="source-ctg-observation-nct07495722-2026-04-29-4571145eb4ea"></a>
- **ClinicalTrials.gov record NCT07495722 · retained source version 2026-04-29:4571145eb4ead547bf4c62e196ed1ee17cf06ed72d36fdbea9cba92356bc5c00** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07495722) (`ctg-observation-nct07495722-2026-04-29-4571145eb4ea`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07495722." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct07495722-pegcetacoplan-v1 SHA-256: 8ebfd6fbf91ede1d82b3bfca6c6716caa9e824b002d82883b55f216647468f3a.

---

<a id="clinicaltrials-gov-nct07746895-pegcetacoplan-v1"></a>

## ClinicalTrials.gov record NCT07746895

> PeptideScanner retained ClinicalTrials.gov record NCT07746895 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

- Evidence object: `story:clinicaltrials-gov-nct07746895-pegcetacoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07746895-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct07746895-pegcetacoplan-v1
- Content SHA-256: `899a9dabd16e2db9c55bff72aa6150732dd8f75d30290fc98e3ba1f6bd335f84`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07746895 ([`ctg-observation-nct07746895-2026-09-09-1f370c6ac1a1`](#source-ctg-observation-nct07746895-2026-09-09-1f370c6ac1a1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07746895 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct07746895-2026-09-09-1f370c6ac1a1`](#source-ctg-observation-nct07746895-2026-09-09-1f370c6ac1a1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07746895 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct07746895-2026-09-09-1f370c6ac1a1`](#source-ctg-observation-nct07746895-2026-09-09-1f370c6ac1a1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07746895-2026-09-09-1f370c6ac1a1`](#source-ctg-observation-nct07746895-2026-09-09-1f370c6ac1a1))

### Sources

<a id="source-ctg-observation-nct07746895-2026-09-09-1f370c6ac1a1"></a>
- **ClinicalTrials.gov record NCT07746895 · retained source version 2026-09-09:1f370c6ac1a1b8f0003d5b76ddb2a180616a589838f03ba0a3f6f79eaf7497a2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07746895) (`ctg-observation-nct07746895-2026-09-09-1f370c6ac1a1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07746895." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct07746895-pegcetacoplan-v1 SHA-256: 899a9dabd16e2db9c55bff72aa6150732dd8f75d30290fc98e3ba1f6bd335f84.

---

<a id="clinicaltrials-gov-nct07898774-pegcetacoplan-v1"></a>

## ClinicalTrials.gov record NCT07898774

> PeptideScanner retained ClinicalTrials.gov record NCT07898774 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

- Evidence object: `story:clinicaltrials-gov-nct07898774-pegcetacoplan:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07898774-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct07898774-pegcetacoplan-v1
- Content SHA-256: `a0bcda1e897c5095910056c7431d99e9d076e706f3ee46642f8dd20909116c63`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07898774 ([`ctg-observation-nct07898774-2026-11-09-852a3429f733`](#source-ctg-observation-nct07898774-2026-11-09-852a3429f733))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07898774 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct07898774-2026-11-09-852a3429f733`](#source-ctg-observation-nct07898774-2026-11-09-852a3429f733))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07898774 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was pegcetacoplan. ([`ctg-observation-nct07898774-2026-11-09-852a3429f733`](#source-ctg-observation-nct07898774-2026-11-09-852a3429f733))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07898774-2026-11-09-852a3429f733`](#source-ctg-observation-nct07898774-2026-11-09-852a3429f733))

### Sources

<a id="source-ctg-observation-nct07898774-2026-11-09-852a3429f733"></a>
- **ClinicalTrials.gov record NCT07898774 · retained source version 2026-11-09:852a3429f733c6a58823688ed68fc0a8c382a5e43f57333e66daccd681d65d8f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07898774) (`ctg-observation-nct07898774-2026-11-09-852a3429f733`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07898774." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#clinicaltrials-gov-nct07898774-pegcetacoplan-v1 SHA-256: a0bcda1e897c5095910056c7431d99e9d076e706f3ee46642f8dd20909116c63.

---

<a id="fda-drugs-nda215014-v1"></a>

## Drugs@FDA application NDA215014

> The official Drugs@FDA dataset lists original submission 1 for NDA 215014 with status AP dated 2021-05-14, and names pegcetacoplan among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda215014:v1`
- Evidence domain: Regulatory
- Date in source: 2021-05-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda215014/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#fda-drugs-nda215014-v1
- Content SHA-256: `08e86e59cc9a743a4b68b97f76ff06b515bef5ddad2d88bdfaf29015b3c632f6`

### Claims and source pins

#### Headline

Drugs@FDA application NDA215014 ([`fda-drugs-nda215014-2021-05-14-d9b31f1f9306`](#source-fda-drugs-nda215014-2021-05-14-d9b31f1f9306))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 215014 with status AP dated 2021-05-14, and names pegcetacoplan among the application record's active ingredients. ([`fda-drugs-nda215014-2021-05-14-d9b31f1f9306`](#source-fda-drugs-nda215014-2021-05-14-d9b31f1f9306))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 215014 with status AP dated 2021-05-14, and names pegcetacoplan among the application record's active ingredients. ([`fda-drugs-nda215014-2021-05-14-d9b31f1f9306`](#source-fda-drugs-nda215014-2021-05-14-d9b31f1f9306))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda215014-2021-05-14-d9b31f1f9306`](#source-fda-drugs-nda215014-2021-05-14-d9b31f1f9306))

### Sources

<a id="source-fda-drugs-nda215014-2021-05-14-d9b31f1f9306"></a>
- **Drugs@FDA application NDA215014 · original submission status AP · 2021-05-14 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA215014%22&limit=1) (`fda-drugs-nda215014-2021-05-14-d9b31f1f9306`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA215014." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#fda-drugs-nda215014-v1 SHA-256: 08e86e59cc9a743a4b68b97f76ff06b515bef5ddad2d88bdfaf29015b3c632f6.

---

<a id="fda-drugs-nda217171-v1"></a>

## Drugs@FDA application NDA217171

> The official Drugs@FDA dataset lists original submission 1 for NDA 217171 with status AP dated 2023-02-17, and names pegcetacoplan among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda217171:v1`
- Evidence domain: Regulatory
- Date in source: 2023-02-17
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda217171/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#fda-drugs-nda217171-v1
- Content SHA-256: `6b08767e8836cbcfe116cdfe6a800ea76f09e09c7bc06e11307c2db14c5fb391`

### Claims and source pins

#### Headline

Drugs@FDA application NDA217171 ([`fda-drugs-nda217171-2023-02-17-728825eaf886`](#source-fda-drugs-nda217171-2023-02-17-728825eaf886))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 217171 with status AP dated 2023-02-17, and names pegcetacoplan among the application record's active ingredients. ([`fda-drugs-nda217171-2023-02-17-728825eaf886`](#source-fda-drugs-nda217171-2023-02-17-728825eaf886))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 217171 with status AP dated 2023-02-17, and names pegcetacoplan among the application record's active ingredients. ([`fda-drugs-nda217171-2023-02-17-728825eaf886`](#source-fda-drugs-nda217171-2023-02-17-728825eaf886))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda217171-2023-02-17-728825eaf886`](#source-fda-drugs-nda217171-2023-02-17-728825eaf886))

### Sources

<a id="source-fda-drugs-nda217171-2023-02-17-728825eaf886"></a>
- **Drugs@FDA application NDA217171 · original submission status AP · 2023-02-17 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA217171%22&limit=1) (`fda-drugs-nda217171-2023-02-17-728825eaf886`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA217171." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#fda-drugs-nda217171-v1 SHA-256: 6b08767e8836cbcfe116cdfe6a800ea76f09e09c7bc06e11307c2db14c5fb391.

---

<a id="federal-register-2023-26255-v1"></a>

## Federal Register notice 2023-26255

> The Federal Register published notice 2023-26255, attributed to FDA and its parent HHS department, on 2023-11-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Empaveli,” and PeptideScanner's exact reviewed identity mapping connects the document to Pegcetacoplan.

- Evidence object: `story:federal-register-2023-26255:v1`
- Evidence domain: Regulatory
- Date in source: 2023-11-29
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-2023-26255/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#federal-register-2023-26255-v1
- Content SHA-256: `316aa90283aceca2cb0c1a1d3339ac1d24369e3d3b9d7c6ca5e94971c1778d3d`

### Claims and source pins

#### Headline

Federal Register notice 2023-26255 ([`federal-register-2023-26255-c09f61d09a64`](#source-federal-register-2023-26255-c09f61d09a64))

#### Summary

The Federal Register published notice 2023-26255, attributed to FDA and its parent HHS department, on 2023-11-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Empaveli,” and PeptideScanner's exact reviewed identity mapping connects the document to Pegcetacoplan. ([`federal-register-2023-26255-c09f61d09a64`](#source-federal-register-2023-26255-c09f61d09a64))

#### Paragraph 1

The Federal Register published notice 2023-26255, attributed to FDA and its parent HHS department, on 2023-11-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Empaveli,” and PeptideScanner's exact reviewed identity mapping connects the document to Pegcetacoplan. ([`federal-register-2023-26255-c09f61d09a64`](#source-federal-register-2023-26255-c09f61d09a64))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2023-26255-c09f61d09a64`](#source-federal-register-2023-26255-c09f61d09a64))

### Sources

<a id="source-federal-register-2023-26255-c09f61d09a64"></a>
- **Federal Register notice 2023-26255 · published 2023-11-29 · Determination of Regulatory Review Period for Purposes of Patent Extension; Empaveli** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2023-11-29/pdf/2023-26255.pdf) (`federal-register-2023-26255-c09f61d09a64`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2023-26255." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#federal-register-2023-26255-v1 SHA-256: 316aa90283aceca2cb0c1a1d3339ac1d24369e3d3b9d7c6ca5e94971c1778d3d.

---

<a id="pubmed-pmid-36965105-pegcetacoplan-v1"></a>

## Fatigue and health-related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data.

> PubMed lists PMID 36965105 in European journal of haematology as Clinical Trial, Phase III, Journal Article, with publication-date metadata of 2023-04-19 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36965105-pegcetacoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36965105-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-36965105-pegcetacoplan-v1
- Content SHA-256: `a30da1fa0352f0eb9175900740a3764cf81447b638c656008dc270db953d518a`

### Claims and source pins

#### Headline

Fatigue and health-related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data. ([`pubmed-observation-pmid-36965105-2026-01-27-eeff640dab55`](#source-pubmed-observation-pmid-36965105-2026-01-27-eeff640dab55))

#### Summary

PubMed lists PMID 36965105 in European journal of haematology as Clinical Trial, Phase III, Journal Article, with publication-date metadata of 2023-04-19 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36965105-2026-01-27-eeff640dab55`](#source-pubmed-observation-pmid-36965105-2026-01-27-eeff640dab55))

#### Paragraph 1

PubMed lists PMID 36965105 in European journal of haematology as Clinical Trial, Phase III, Journal Article, with publication-date metadata of 2023-04-19 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36965105-2026-01-27-eeff640dab55`](#source-pubmed-observation-pmid-36965105-2026-01-27-eeff640dab55))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36965105-2026-01-27-eeff640dab55`](#source-pubmed-observation-pmid-36965105-2026-01-27-eeff640dab55))

### Sources

<a id="source-pubmed-observation-pmid-36965105-2026-01-27-eeff640dab55"></a>
- **Fatigue and health-related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data. · retained source version 1:2026-01-27:current:eeff640dab5554ea936e374173c271c7c9fdc01e16e254bac62461bae564fcf1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36965105/) (`pubmed-observation-pmid-36965105-2026-01-27-eeff640dab55`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Fatigue and health-related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-36965105-pegcetacoplan-v1 SHA-256: a30da1fa0352f0eb9175900740a3764cf81447b638c656008dc270db953d518a.

---

<a id="pubmed-pmid-37195551-pegcetacoplan-v1"></a>

## Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

> PubMed lists PMID 37195551 in PharmacoEconomics - open as Journal Article, Review, with publication-date metadata of 2023-05-17 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37195551-pegcetacoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-07-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37195551-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-37195551-pegcetacoplan-v1
- Content SHA-256: `99eeebe072b25a5bc2c17a501070fe372346a637058a5643a9e5664a4c2f1f16`

### Claims and source pins

#### Headline

Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. ([`pubmed-observation-pmid-37195551-2023-07-18-014f7a1c5acf`](#source-pubmed-observation-pmid-37195551-2023-07-18-014f7a1c5acf))

#### Summary

PubMed lists PMID 37195551 in PharmacoEconomics - open as Journal Article, Review, with publication-date metadata of 2023-05-17 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37195551-2023-07-18-014f7a1c5acf`](#source-pubmed-observation-pmid-37195551-2023-07-18-014f7a1c5acf))

#### Paragraph 1

PubMed lists PMID 37195551 in PharmacoEconomics - open as Journal Article, Review, with publication-date metadata of 2023-05-17 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37195551-2023-07-18-014f7a1c5acf`](#source-pubmed-observation-pmid-37195551-2023-07-18-014f7a1c5acf))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37195551-2023-07-18-014f7a1c5acf`](#source-pubmed-observation-pmid-37195551-2023-07-18-014f7a1c5acf))

### Sources

<a id="source-pubmed-observation-pmid-37195551-2023-07-18-014f7a1c5acf"></a>
- **Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. · retained source version 1:2023-07-18:current:014f7a1c5acf6e63e59c7261bd20f7a2ca89a4db3c50e579c6be6f712bcdedd9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37195551/) (`pubmed-observation-pmid-37195551-2023-07-18-014f7a1c5acf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-37195551-pegcetacoplan-v1 SHA-256: 99eeebe072b25a5bc2c17a501070fe372346a637058a5643a9e5664a4c2f1f16.

---

<a id="pubmed-pmid-37259853-pegcetacoplan-v1"></a>

## WITHDRAWN: Pegcetacoplan in the treatment of geographic atrophy.

> PubMed lists PMID 37259853 in Immunotherapy as Journal Article, Review, with publication-date metadata of 2023-06-01 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37259853-pegcetacoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-06-06
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37259853-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-37259853-pegcetacoplan-v1
- Content SHA-256: `2868e3b71f87b051d62bd62d7ab01978cebd9c53d5f49d56e8a89cbbbc2252c8`

### Claims and source pins

#### Headline

WITHDRAWN: Pegcetacoplan in the treatment of geographic atrophy. ([`pubmed-observation-pmid-37259853-2023-06-06-a5bd3b6edd91`](#source-pubmed-observation-pmid-37259853-2023-06-06-a5bd3b6edd91))

#### Summary

PubMed lists PMID 37259853 in Immunotherapy as Journal Article, Review, with publication-date metadata of 2023-06-01 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37259853-2023-06-06-a5bd3b6edd91`](#source-pubmed-observation-pmid-37259853-2023-06-06-a5bd3b6edd91))

#### Paragraph 1

PubMed lists PMID 37259853 in Immunotherapy as Journal Article, Review, with publication-date metadata of 2023-06-01 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37259853-2023-06-06-a5bd3b6edd91`](#source-pubmed-observation-pmid-37259853-2023-06-06-a5bd3b6edd91))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37259853-2023-06-06-a5bd3b6edd91`](#source-pubmed-observation-pmid-37259853-2023-06-06-a5bd3b6edd91))

### Sources

<a id="source-pubmed-observation-pmid-37259853-2023-06-06-a5bd3b6edd91"></a>
- **WITHDRAWN: Pegcetacoplan in the treatment of geographic atrophy. · retained source version 1:2023-06-06:current:a5bd3b6edd913f632f249ce8bd096db791e0e43f3edce3a4ee959d4c2fd844b7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37259853/) (`pubmed-observation-pmid-37259853-2023-06-06-a5bd3b6edd91`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "WITHDRAWN: Pegcetacoplan in the treatment of geographic atrophy." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-37259853-pegcetacoplan-v1 SHA-256: 2868e3b71f87b051d62bd62d7ab01978cebd9c53d5f49d56e8a89cbbbc2252c8.

---

<a id="pubmed-pmid-37815317-pegcetacoplan-v1"></a>

## Treatment of geographic atrophy: an update on data related to pegcetacoplan.

> PubMed lists PMID 37815317 in Current opinion in ophthalmology as Review, Journal Article, with publication-date metadata of 2023-10-10 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37815317-pegcetacoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-07-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37815317-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-37815317-pegcetacoplan-v1
- Content SHA-256: `8497f8c72265188badc2885fc9b4b61969ffb73034c03ab6ee922931a5ee2829`

### Claims and source pins

#### Headline

Treatment of geographic atrophy: an update on data related to pegcetacoplan. ([`pubmed-observation-pmid-37815317-2025-07-30-fa7a20e66103`](#source-pubmed-observation-pmid-37815317-2025-07-30-fa7a20e66103))

#### Summary

PubMed lists PMID 37815317 in Current opinion in ophthalmology as Review, Journal Article, with publication-date metadata of 2023-10-10 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37815317-2025-07-30-fa7a20e66103`](#source-pubmed-observation-pmid-37815317-2025-07-30-fa7a20e66103))

#### Paragraph 1

PubMed lists PMID 37815317 in Current opinion in ophthalmology as Review, Journal Article, with publication-date metadata of 2023-10-10 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37815317-2025-07-30-fa7a20e66103`](#source-pubmed-observation-pmid-37815317-2025-07-30-fa7a20e66103))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37815317-2025-07-30-fa7a20e66103`](#source-pubmed-observation-pmid-37815317-2025-07-30-fa7a20e66103))

### Sources

<a id="source-pubmed-observation-pmid-37815317-2025-07-30-fa7a20e66103"></a>
- **Treatment of geographic atrophy: an update on data related to pegcetacoplan. · retained source version 1:2025-07-30:current:fa7a20e661033fffddd6bb73c56edcc93782bc33b65d64394729a15808d4b6b3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37815317/) (`pubmed-observation-pmid-37815317-2025-07-30-fa7a20e66103`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Treatment of geographic atrophy: an update on data related to pegcetacoplan." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-37815317-pegcetacoplan-v1 SHA-256: 8497f8c72265188badc2885fc9b4b61969ffb73034c03ab6ee922931a5ee2829.

---

<a id="pubmed-pmid-38098608-pegcetacoplan-v1"></a>

## Advancements in the treatment of geographic atrophy: focus on pegcetacoplan in age-related macular degeneration.

> PubMed lists PMID 38098608 in Annals of medicine and surgery (2012) as Journal Article, Review, with publication-date metadata of 2023-11-01 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38098608-pegcetacoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-12-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38098608-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-38098608-pegcetacoplan-v1
- Content SHA-256: `3329fd5733877000f69b23e63126ec90501253837b2c49e0f5140de1602cc216`

### Claims and source pins

#### Headline

Advancements in the treatment of geographic atrophy: focus on pegcetacoplan in age-related macular degeneration. ([`pubmed-observation-pmid-38098608-2023-12-16-6cbae629cab3`](#source-pubmed-observation-pmid-38098608-2023-12-16-6cbae629cab3))

#### Summary

PubMed lists PMID 38098608 in Annals of medicine and surgery (2012) as Journal Article, Review, with publication-date metadata of 2023-11-01 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38098608-2023-12-16-6cbae629cab3`](#source-pubmed-observation-pmid-38098608-2023-12-16-6cbae629cab3))

#### Paragraph 1

PubMed lists PMID 38098608 in Annals of medicine and surgery (2012) as Journal Article, Review, with publication-date metadata of 2023-11-01 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38098608-2023-12-16-6cbae629cab3`](#source-pubmed-observation-pmid-38098608-2023-12-16-6cbae629cab3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38098608-2023-12-16-6cbae629cab3`](#source-pubmed-observation-pmid-38098608-2023-12-16-6cbae629cab3))

### Sources

<a id="source-pubmed-observation-pmid-38098608-2023-12-16-6cbae629cab3"></a>
- **Advancements in the treatment of geographic atrophy: focus on pegcetacoplan in age-related macular degeneration. · retained source version 1:2023-12-16:current:6cbae629cab39e9a8ad202208d61b873c50c2f47f50edb4b993131d55ea37dc7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38098608/) (`pubmed-observation-pmid-38098608-2023-12-16-6cbae629cab3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Advancements in the treatment of geographic atrophy: focus on pegcetacoplan in age-related macular degeneration." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-38098608-pegcetacoplan-v1 SHA-256: 3329fd5733877000f69b23e63126ec90501253837b2c49e0f5140de1602cc216.

---

<a id="pubmed-pmid-38453703-pegcetacoplan-v1"></a>

## Development of a target concentration intervention to individualize paroxysmal nocturnal hemoglobinuria treatment with pegcetacoplan.

> PubMed lists PMID 38453703 in Annals of hematology as Journal Article, Clinical Trial, with publication-date metadata of 2024-03-08 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38453703-pegcetacoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-09-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38453703-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-38453703-pegcetacoplan-v1
- Content SHA-256: `624767f23d28258b7e9a185d8ff992e2e63d277c73542272dd08a80f17714eed`

### Claims and source pins

#### Headline

Development of a target concentration intervention to individualize paroxysmal nocturnal hemoglobinuria treatment with pegcetacoplan. ([`pubmed-observation-pmid-38453703-2024-09-18-4232ab70a5c6`](#source-pubmed-observation-pmid-38453703-2024-09-18-4232ab70a5c6))

#### Summary

PubMed lists PMID 38453703 in Annals of hematology as Journal Article, Clinical Trial, with publication-date metadata of 2024-03-08 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38453703-2024-09-18-4232ab70a5c6`](#source-pubmed-observation-pmid-38453703-2024-09-18-4232ab70a5c6))

#### Paragraph 1

PubMed lists PMID 38453703 in Annals of hematology as Journal Article, Clinical Trial, with publication-date metadata of 2024-03-08 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38453703-2024-09-18-4232ab70a5c6`](#source-pubmed-observation-pmid-38453703-2024-09-18-4232ab70a5c6))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38453703-2024-09-18-4232ab70a5c6`](#source-pubmed-observation-pmid-38453703-2024-09-18-4232ab70a5c6))

### Sources

<a id="source-pubmed-observation-pmid-38453703-2024-09-18-4232ab70a5c6"></a>
- **Development of a target concentration intervention to individualize paroxysmal nocturnal hemoglobinuria treatment with pegcetacoplan. · retained source version 1:2024-09-18:current:4232ab70a5c6d0a92e5e46707775f77236de96a15ae5533b5965ef98ecf5525e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38453703/) (`pubmed-observation-pmid-38453703-2024-09-18-4232ab70a5c6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Development of a target concentration intervention to individualize paroxysmal nocturnal hemoglobinuria treatment with pegcetacoplan." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-38453703-pegcetacoplan-v1 SHA-256: 624767f23d28258b7e9a185d8ff992e2e63d277c73542272dd08a80f17714eed.

---

<a id="pubmed-pmid-38593241-pegcetacoplan-v1"></a>

## Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria.

> PubMed lists PMID 38593241 in Blood advances as Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-06-11 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38593241-pegcetacoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-11-06
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38593241-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-38593241-pegcetacoplan-v1
- Content SHA-256: `8e599662174d711af3e171f5d9794830dec386f90ad6891567b9182cd5734b0e`

### Claims and source pins

#### Headline

Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria. ([`pubmed-observation-pmid-38593241-2024-11-06-5d5bd8248782`](#source-pubmed-observation-pmid-38593241-2024-11-06-5d5bd8248782))

#### Summary

PubMed lists PMID 38593241 in Blood advances as Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-06-11 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38593241-2024-11-06-5d5bd8248782`](#source-pubmed-observation-pmid-38593241-2024-11-06-5d5bd8248782))

#### Paragraph 1

PubMed lists PMID 38593241 in Blood advances as Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-06-11 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38593241-2024-11-06-5d5bd8248782`](#source-pubmed-observation-pmid-38593241-2024-11-06-5d5bd8248782))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38593241-2024-11-06-5d5bd8248782`](#source-pubmed-observation-pmid-38593241-2024-11-06-5d5bd8248782))

### Sources

<a id="source-pubmed-observation-pmid-38593241-2024-11-06-5d5bd8248782"></a>
- **Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria. · retained source version 1:2024-11-06:current:5d5bd824878253a7a979f4a4d4dced8fecfb10d8f3dd2a833c9549e9840b3a4a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38593241/) (`pubmed-observation-pmid-38593241-2024-11-06-5d5bd8248782`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-38593241-pegcetacoplan-v1 SHA-256: 8e599662174d711af3e171f5d9794830dec386f90ad6891567b9182cd5734b0e.

---

<a id="pubmed-pmid-38722644-pegcetacoplan-v1"></a>

## Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months.

> PubMed lists PMID 38722644 in JAMA ophthalmology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2024-06-01 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38722644-pegcetacoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38722644-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-38722644-pegcetacoplan-v1
- Content SHA-256: `34db5c8474af89713894e83c9d06a211e7ac533b7a21f1b0c0f57d9106103bfd`

### Claims and source pins

#### Headline

Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months. ([`pubmed-observation-pmid-38722644-2026-08-27-fee8c87d901b`](#source-pubmed-observation-pmid-38722644-2026-08-27-fee8c87d901b))

#### Summary

PubMed lists PMID 38722644 in JAMA ophthalmology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2024-06-01 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38722644-2026-08-27-fee8c87d901b`](#source-pubmed-observation-pmid-38722644-2026-08-27-fee8c87d901b))

#### Paragraph 1

PubMed lists PMID 38722644 in JAMA ophthalmology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2024-06-01 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38722644-2026-08-27-fee8c87d901b`](#source-pubmed-observation-pmid-38722644-2026-08-27-fee8c87d901b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38722644-2026-08-27-fee8c87d901b`](#source-pubmed-observation-pmid-38722644-2026-08-27-fee8c87d901b))

### Sources

<a id="source-pubmed-observation-pmid-38722644-2026-08-27-fee8c87d901b"></a>
- **Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months. · retained source version 1:2026-08-27:current:fee8c87d901b7c336a1561c9fe939a8ae1e79664f38f35242d783078153cfcf5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38722644/) (`pubmed-observation-pmid-38722644-2026-08-27-fee8c87d901b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-38722644-pegcetacoplan-v1 SHA-256: 34db5c8474af89713894e83c9d06a211e7ac533b7a21f1b0c0f57d9106103bfd.

---

<a id="pubmed-pmid-38727860-pegcetacoplan-v1"></a>

## Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan.

> PubMed lists PMID 38727860 in Drugs in R&D as Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial, with publication-date metadata of 2024-05-10 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38727860-pegcetacoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-01-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38727860-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-38727860-pegcetacoplan-v1
- Content SHA-256: `a0e58b7062f4f9f324608e395c77371215b0910e77bd35a556bf5c4f025063ac`

### Claims and source pins

#### Headline

Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan. ([`pubmed-observation-pmid-38727860-2025-01-27-f8f2b5718eb7`](#source-pubmed-observation-pmid-38727860-2025-01-27-f8f2b5718eb7))

#### Summary

PubMed lists PMID 38727860 in Drugs in R&D as Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial, with publication-date metadata of 2024-05-10 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38727860-2025-01-27-f8f2b5718eb7`](#source-pubmed-observation-pmid-38727860-2025-01-27-f8f2b5718eb7))

#### Paragraph 1

PubMed lists PMID 38727860 in Drugs in R&D as Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial, with publication-date metadata of 2024-05-10 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38727860-2025-01-27-f8f2b5718eb7`](#source-pubmed-observation-pmid-38727860-2025-01-27-f8f2b5718eb7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38727860-2025-01-27-f8f2b5718eb7`](#source-pubmed-observation-pmid-38727860-2025-01-27-f8f2b5718eb7))

### Sources

<a id="source-pubmed-observation-pmid-38727860-2025-01-27-f8f2b5718eb7"></a>
- **Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan. · retained source version 1:2025-01-27:current:f8f2b5718eb781c2317aefd2b4d7e8c7640fa8ec68e4d4bdedc2d4b768dde63b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38727860/) (`pubmed-observation-pmid-38727860-2025-01-27-f8f2b5718eb7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-38727860-pegcetacoplan-v1 SHA-256: a0e58b7062f4f9f324608e395c77371215b0910e77bd35a556bf5c4f025063ac.

---

<a id="pubmed-pmid-39201278-pegcetacoplan-v1"></a>

## Moving toward Individual Treatment Goals with Pegcetacoplan in Patients with PNH and Impaired Bone Marrow Function.

> PubMed lists PMID 39201278 in International journal of molecular sciences as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2024-08-06 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39201278-pegcetacoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-09-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39201278-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-39201278-pegcetacoplan-v1
- Content SHA-256: `909d75500dca0caac9c0a7c183dd3434c3a035a593b52a28e37bec5d3cc9e0e1`

### Claims and source pins

#### Headline

Moving toward Individual Treatment Goals with Pegcetacoplan in Patients with PNH and Impaired Bone Marrow Function. ([`pubmed-observation-pmid-39201278-2024-09-03-772387b77482`](#source-pubmed-observation-pmid-39201278-2024-09-03-772387b77482))

#### Summary

PubMed lists PMID 39201278 in International journal of molecular sciences as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2024-08-06 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39201278-2024-09-03-772387b77482`](#source-pubmed-observation-pmid-39201278-2024-09-03-772387b77482))

#### Paragraph 1

PubMed lists PMID 39201278 in International journal of molecular sciences as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2024-08-06 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39201278-2024-09-03-772387b77482`](#source-pubmed-observation-pmid-39201278-2024-09-03-772387b77482))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39201278-2024-09-03-772387b77482`](#source-pubmed-observation-pmid-39201278-2024-09-03-772387b77482))

### Sources

<a id="source-pubmed-observation-pmid-39201278-2024-09-03-772387b77482"></a>
- **Moving toward Individual Treatment Goals with Pegcetacoplan in Patients with PNH and Impaired Bone Marrow Function. · retained source version 1:2024-09-03:current:772387b77482eaefca5bf512a33f038114d074ddc88698d5a4320c725a695a0d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39201278/) (`pubmed-observation-pmid-39201278-2024-09-03-772387b77482`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Moving toward Individual Treatment Goals with Pegcetacoplan in Patients with PNH and Impaired Bone Marrow Function." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-39201278-pegcetacoplan-v1 SHA-256: 909d75500dca0caac9c0a7c183dd3434c3a035a593b52a28e37bec5d3cc9e0e1.

---

<a id="pubmed-pmid-39497616-pegcetacoplan-v1"></a>

## Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham.

> PubMed lists PMID 39497616 in CPT: pharmacometrics & systems pharmacology as Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2024-11-05 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39497616-pegcetacoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-24
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39497616-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-39497616-pegcetacoplan-v1
- Content SHA-256: `c10b1b3ee4dd1e0a2379a2ef668dedf2762709daa25e3b6cc346080183006d13`

### Claims and source pins

#### Headline

Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham. ([`pubmed-observation-pmid-39497616-2026-09-24-2d3e27b983b4`](#source-pubmed-observation-pmid-39497616-2026-09-24-2d3e27b983b4))

#### Summary

PubMed lists PMID 39497616 in CPT: pharmacometrics & systems pharmacology as Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2024-11-05 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39497616-2026-09-24-2d3e27b983b4`](#source-pubmed-observation-pmid-39497616-2026-09-24-2d3e27b983b4))

#### Paragraph 1

PubMed lists PMID 39497616 in CPT: pharmacometrics & systems pharmacology as Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2024-11-05 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39497616-2026-09-24-2d3e27b983b4`](#source-pubmed-observation-pmid-39497616-2026-09-24-2d3e27b983b4))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39497616-2026-09-24-2d3e27b983b4`](#source-pubmed-observation-pmid-39497616-2026-09-24-2d3e27b983b4))

### Sources

<a id="source-pubmed-observation-pmid-39497616-2026-09-24-2d3e27b983b4"></a>
- **Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham. · retained source version 1:2026-09-24:current:2d3e27b983b4da42b1bb5e6433b4b923006049837442eef7653bd693ea173fe4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39497616/) (`pubmed-observation-pmid-39497616-2026-09-24-2d3e27b983b4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-39497616-pegcetacoplan-v1 SHA-256: c10b1b3ee4dd1e0a2379a2ef668dedf2762709daa25e3b6cc346080183006d13.

---

<a id="pubmed-pmid-39656072-pegcetacoplan-v1"></a>

## Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria.

> PubMed lists PMID 39656072 in Expert review of hematology as Journal Article, Review, with publication-date metadata of 2024-12-16 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39656072-pegcetacoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39656072-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-39656072-pegcetacoplan-v1
- Content SHA-256: `fadda1304083f64b6a002bd8651256a5a0d85702fbd9d3c6006bf69ee92a1f46`

### Claims and source pins

#### Headline

Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria. ([`pubmed-observation-pmid-39656072-2026-09-01-46dc0ae7b9ca`](#source-pubmed-observation-pmid-39656072-2026-09-01-46dc0ae7b9ca))

#### Summary

PubMed lists PMID 39656072 in Expert review of hematology as Journal Article, Review, with publication-date metadata of 2024-12-16 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39656072-2026-09-01-46dc0ae7b9ca`](#source-pubmed-observation-pmid-39656072-2026-09-01-46dc0ae7b9ca))

#### Paragraph 1

PubMed lists PMID 39656072 in Expert review of hematology as Journal Article, Review, with publication-date metadata of 2024-12-16 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39656072-2026-09-01-46dc0ae7b9ca`](#source-pubmed-observation-pmid-39656072-2026-09-01-46dc0ae7b9ca))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39656072-2026-09-01-46dc0ae7b9ca`](#source-pubmed-observation-pmid-39656072-2026-09-01-46dc0ae7b9ca))

### Sources

<a id="source-pubmed-observation-pmid-39656072-2026-09-01-46dc0ae7b9ca"></a>
- **Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria. · retained source version 1:2026-09-01:current:46dc0ae7b9ca8131c1385916c79fe2c7be2652b96f103146d0fc3889a64ddb05** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39656072/) (`pubmed-observation-pmid-39656072-2026-09-01-46dc0ae7b9ca`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-39656072-pegcetacoplan-v1 SHA-256: fadda1304083f64b6a002bd8651256a5a0d85702fbd9d3c6006bf69ee92a1f46.

---

<a id="pubmed-pmid-40280279-pegcetacoplan-v1"></a>

## Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE.

> PubMed lists PMID 40280279 in American journal of ophthalmology as Journal Article, Clinical Trial, Phase III, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2025-04-23 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40280279-pegcetacoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-07-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40280279-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-40280279-pegcetacoplan-v1
- Content SHA-256: `07b405917e0514fc2af1eb62914b9045dd1ef9f7058e181997b0e68ccd5d2136`

### Claims and source pins

#### Headline

Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE. ([`pubmed-observation-pmid-40280279-2025-07-15-b5c2fda2e88a`](#source-pubmed-observation-pmid-40280279-2025-07-15-b5c2fda2e88a))

#### Summary

PubMed lists PMID 40280279 in American journal of ophthalmology as Journal Article, Clinical Trial, Phase III, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2025-04-23 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40280279-2025-07-15-b5c2fda2e88a`](#source-pubmed-observation-pmid-40280279-2025-07-15-b5c2fda2e88a))

#### Paragraph 1

PubMed lists PMID 40280279 in American journal of ophthalmology as Journal Article, Clinical Trial, Phase III, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2025-04-23 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40280279-2025-07-15-b5c2fda2e88a`](#source-pubmed-observation-pmid-40280279-2025-07-15-b5c2fda2e88a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40280279-2025-07-15-b5c2fda2e88a`](#source-pubmed-observation-pmid-40280279-2025-07-15-b5c2fda2e88a))

### Sources

<a id="source-pubmed-observation-pmid-40280279-2025-07-15-b5c2fda2e88a"></a>
- **Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE. · retained source version 1:2025-07-15:current:b5c2fda2e88ac49c325c6c87fc0d70ac3fac3de95d48cbe741322116290363e3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40280279/) (`pubmed-observation-pmid-40280279-2025-07-15-b5c2fda2e88a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-40280279-pegcetacoplan-v1 SHA-256: 07b405917e0514fc2af1eb62914b9045dd1ef9f7058e181997b0e68ccd5d2136.

---

<a id="pubmed-pmid-40833323-pegcetacoplan-v1"></a>

## Dynamics of the EZ/RPE Loss Ratio on OCT Over Time During Geographic Atrophy Progression and Treatment With Pegcetacoplan.

> PubMed lists PMID 40833323 in Investigative ophthalmology & visual science as Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-08-01 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40833323-pegcetacoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-23
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40833323-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-40833323-pegcetacoplan-v1
- Content SHA-256: `2ce898c4688e46882370171d3f87c94577bec205e98f897ac6318e6c3b73336c`

### Claims and source pins

#### Headline

Dynamics of the EZ/RPE Loss Ratio on OCT Over Time During Geographic Atrophy Progression and Treatment With Pegcetacoplan. ([`pubmed-observation-pmid-40833323-2026-08-23-3e0a1561d2d5`](#source-pubmed-observation-pmid-40833323-2026-08-23-3e0a1561d2d5))

#### Summary

PubMed lists PMID 40833323 in Investigative ophthalmology & visual science as Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-08-01 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40833323-2026-08-23-3e0a1561d2d5`](#source-pubmed-observation-pmid-40833323-2026-08-23-3e0a1561d2d5))

#### Paragraph 1

PubMed lists PMID 40833323 in Investigative ophthalmology & visual science as Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-08-01 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40833323-2026-08-23-3e0a1561d2d5`](#source-pubmed-observation-pmid-40833323-2026-08-23-3e0a1561d2d5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40833323-2026-08-23-3e0a1561d2d5`](#source-pubmed-observation-pmid-40833323-2026-08-23-3e0a1561d2d5))

### Sources

<a id="source-pubmed-observation-pmid-40833323-2026-08-23-3e0a1561d2d5"></a>
- **Dynamics of the EZ/RPE Loss Ratio on OCT Over Time During Geographic Atrophy Progression and Treatment With Pegcetacoplan. · retained source version 1:2026-08-23:current:3e0a1561d2d5d2e6c817d7ffa1f4b587dcd9908ea722df5a8c7ff2487aba1478** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40833323/) (`pubmed-observation-pmid-40833323-2026-08-23-3e0a1561d2d5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Dynamics of the EZ/RPE Loss Ratio on OCT Over Time During Geographic Atrophy Progression and Treatment With Pegcetacoplan." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-40833323-pegcetacoplan-v1 SHA-256: 2ce898c4688e46882370171d3f87c94577bec205e98f897ac6318e6c3b73336c.

---

<a id="pubmed-pmid-41337715-pegcetacoplan-v1"></a>

## Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN.

> PubMed lists PMID 41337715 in The New England journal of medicine as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, with publication-date metadata of 2025-12-04 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41337715-pegcetacoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-03-11
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41337715-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-41337715-pegcetacoplan-v1
- Content SHA-256: `c8759b5f608f9862f2143bb54d0ac0dcdaba7382ca80fbe117225c39750b4062`

### Claims and source pins

#### Headline

Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. ([`pubmed-observation-pmid-41337715-2026-03-11-5a390de30118`](#source-pubmed-observation-pmid-41337715-2026-03-11-5a390de30118))

#### Summary

PubMed lists PMID 41337715 in The New England journal of medicine as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, with publication-date metadata of 2025-12-04 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41337715-2026-03-11-5a390de30118`](#source-pubmed-observation-pmid-41337715-2026-03-11-5a390de30118))

#### Paragraph 1

PubMed lists PMID 41337715 in The New England journal of medicine as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, with publication-date metadata of 2025-12-04 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41337715-2026-03-11-5a390de30118`](#source-pubmed-observation-pmid-41337715-2026-03-11-5a390de30118))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41337715-2026-03-11-5a390de30118`](#source-pubmed-observation-pmid-41337715-2026-03-11-5a390de30118))

### Sources

<a id="source-pubmed-observation-pmid-41337715-2026-03-11-5a390de30118"></a>
- **Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. · retained source version 1:2026-03-11:current:5a390de30118a14956317982be5bf5846d42d5fa435fa69902e07ae87f610da5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41337715/) (`pubmed-observation-pmid-41337715-2026-03-11-5a390de30118`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-41337715-pegcetacoplan-v1 SHA-256: c8759b5f608f9862f2143bb54d0ac0dcdaba7382ca80fbe117225c39750b4062.

---

<a id="pubmed-pmid-42022788-pegcetacoplan-v1"></a>

## Direct Switch From Iptacopan to Pegcetacoplan in a Patient With Paroxysmal Nocturnal Hemoglobinuria.

> PubMed lists PMID 42022788 in EJHaem as Journal Article, with publication-date metadata of 2026-04-21 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42022788-pegcetacoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42022788-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-42022788-pegcetacoplan-v1
- Content SHA-256: `10bf2fc928d8e22b3ffd9d1bec974b12f6c00c0d47397e1a091710bbc1283528`

### Claims and source pins

#### Headline

Direct Switch From Iptacopan to Pegcetacoplan in a Patient With Paroxysmal Nocturnal Hemoglobinuria. ([`pubmed-observation-pmid-42022788-2026-08-13-68a2c6715966`](#source-pubmed-observation-pmid-42022788-2026-08-13-68a2c6715966))

#### Summary

PubMed lists PMID 42022788 in EJHaem as Journal Article, with publication-date metadata of 2026-04-21 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42022788-2026-08-13-68a2c6715966`](#source-pubmed-observation-pmid-42022788-2026-08-13-68a2c6715966))

#### Paragraph 1

PubMed lists PMID 42022788 in EJHaem as Journal Article, with publication-date metadata of 2026-04-21 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42022788-2026-08-13-68a2c6715966`](#source-pubmed-observation-pmid-42022788-2026-08-13-68a2c6715966))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42022788-2026-08-13-68a2c6715966`](#source-pubmed-observation-pmid-42022788-2026-08-13-68a2c6715966))

### Sources

<a id="source-pubmed-observation-pmid-42022788-2026-08-13-68a2c6715966"></a>
- **Direct Switch From Iptacopan to Pegcetacoplan in a Patient With Paroxysmal Nocturnal Hemoglobinuria. · retained source version 1:2026-08-13:current:68a2c67159668ce369180a5849f56ba2067d4bf04f024790dce44134c0d58f4b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42022788/) (`pubmed-observation-pmid-42022788-2026-08-13-68a2c6715966`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Direct Switch From Iptacopan to Pegcetacoplan in a Patient With Paroxysmal Nocturnal Hemoglobinuria." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-42022788-pegcetacoplan-v1 SHA-256: 10bf2fc928d8e22b3ffd9d1bec974b12f6c00c0d47397e1a091710bbc1283528.

---

<a id="pubmed-pmid-42061561-pegcetacoplan-v1"></a>

## Pegcetacoplan prophylaxis for recurrent C3 glomerulopathy with multifactorial genetic background.

> PubMed lists PMID 42061561 in Kidney international as Case Reports, Journal Article, with publication-date metadata of 2026-04-28 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42061561-pegcetacoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42061561-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-42061561-pegcetacoplan-v1
- Content SHA-256: `390fef655f1d953ca52824d4663484af84a28a56c38bd4e2207c937c9e579553`

### Claims and source pins

#### Headline

Pegcetacoplan prophylaxis for recurrent C3 glomerulopathy with multifactorial genetic background. ([`pubmed-observation-pmid-42061561-2026-07-20-22571f6b7c8b`](#source-pubmed-observation-pmid-42061561-2026-07-20-22571f6b7c8b))

#### Summary

PubMed lists PMID 42061561 in Kidney international as Case Reports, Journal Article, with publication-date metadata of 2026-04-28 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42061561-2026-07-20-22571f6b7c8b`](#source-pubmed-observation-pmid-42061561-2026-07-20-22571f6b7c8b))

#### Paragraph 1

PubMed lists PMID 42061561 in Kidney international as Case Reports, Journal Article, with publication-date metadata of 2026-04-28 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42061561-2026-07-20-22571f6b7c8b`](#source-pubmed-observation-pmid-42061561-2026-07-20-22571f6b7c8b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42061561-2026-07-20-22571f6b7c8b`](#source-pubmed-observation-pmid-42061561-2026-07-20-22571f6b7c8b))

### Sources

<a id="source-pubmed-observation-pmid-42061561-2026-07-20-22571f6b7c8b"></a>
- **Pegcetacoplan prophylaxis for recurrent C3 glomerulopathy with multifactorial genetic background. · retained source version 1:2026-07-20:current:22571f6b7c8b8f39a8ae7b413b4e492a93c39d488bbe65a79373acec6b933eec** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42061561/) (`pubmed-observation-pmid-42061561-2026-07-20-22571f6b7c8b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pegcetacoplan prophylaxis for recurrent C3 glomerulopathy with multifactorial genetic background." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-42061561-pegcetacoplan-v1 SHA-256: 390fef655f1d953ca52824d4663484af84a28a56c38bd4e2207c937c9e579553.

---

<a id="pubmed-pmid-42133432-pegcetacoplan-v1"></a>

## Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN: Phase 3 VALIANT Subgroup Analysis.

> PubMed lists PMID 42133432 in Clinical journal of the American Society of Nephrology : CJASN as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, with publication-date metadata of 2026-05-14 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42133432-pegcetacoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42133432-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-42133432-pegcetacoplan-v1
- Content SHA-256: `4b22cab404d87c50942eaadcad54f05d34bff07d09bc3032bd089f00ea7a2b8c`

### Claims and source pins

#### Headline

Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN: Phase 3 VALIANT Subgroup Analysis. ([`pubmed-observation-pmid-42133432-2026-08-28-fe6e27b37813`](#source-pubmed-observation-pmid-42133432-2026-08-28-fe6e27b37813))

#### Summary

PubMed lists PMID 42133432 in Clinical journal of the American Society of Nephrology : CJASN as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, with publication-date metadata of 2026-05-14 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42133432-2026-08-28-fe6e27b37813`](#source-pubmed-observation-pmid-42133432-2026-08-28-fe6e27b37813))

#### Paragraph 1

PubMed lists PMID 42133432 in Clinical journal of the American Society of Nephrology : CJASN as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, with publication-date metadata of 2026-05-14 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42133432-2026-08-28-fe6e27b37813`](#source-pubmed-observation-pmid-42133432-2026-08-28-fe6e27b37813))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42133432-2026-08-28-fe6e27b37813`](#source-pubmed-observation-pmid-42133432-2026-08-28-fe6e27b37813))

### Sources

<a id="source-pubmed-observation-pmid-42133432-2026-08-28-fe6e27b37813"></a>
- **Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN: Phase 3 VALIANT Subgroup Analysis. · retained source version 1:2026-08-28:current:fe6e27b378136a02133f0ff3dadc5fb9769610ccaea5b10b70bbe00d58885484** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42133432/) (`pubmed-observation-pmid-42133432-2026-08-28-fe6e27b37813`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN: Phase 3 VALIANT Subgroup Analysis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-42133432-pegcetacoplan-v1 SHA-256: 4b22cab404d87c50942eaadcad54f05d34bff07d09bc3032bd089f00ea7a2b8c.

---

<a id="pubmed-pmid-42138781-pegcetacoplan-v1"></a>

## Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons.

> PubMed lists PMID 42138781 in Advances in therapy as Clinical Trial, Phase III, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2026-05-15 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42138781-pegcetacoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-26
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42138781-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-42138781-pegcetacoplan-v1
- Content SHA-256: `98b77fc41c08a4e2d6c9765bdb48ef850d1662dd63cbd67bd0a4b28b826afd2e`

### Claims and source pins

#### Headline

Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons. ([`pubmed-observation-pmid-42138781-2026-08-26-d3ac622683d3`](#source-pubmed-observation-pmid-42138781-2026-08-26-d3ac622683d3))

#### Summary

PubMed lists PMID 42138781 in Advances in therapy as Clinical Trial, Phase III, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2026-05-15 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42138781-2026-08-26-d3ac622683d3`](#source-pubmed-observation-pmid-42138781-2026-08-26-d3ac622683d3))

#### Paragraph 1

PubMed lists PMID 42138781 in Advances in therapy as Clinical Trial, Phase III, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2026-05-15 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42138781-2026-08-26-d3ac622683d3`](#source-pubmed-observation-pmid-42138781-2026-08-26-d3ac622683d3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42138781-2026-08-26-d3ac622683d3`](#source-pubmed-observation-pmid-42138781-2026-08-26-d3ac622683d3))

### Sources

<a id="source-pubmed-observation-pmid-42138781-2026-08-26-d3ac622683d3"></a>
- **Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons. · retained source version 1:2026-08-26:current:d3ac622683d32abeca5fdea88cce2ad0c6bb01071a8385658686f2d4f383809b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42138781/) (`pubmed-observation-pmid-42138781-2026-08-26-d3ac622683d3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-42138781-pegcetacoplan-v1 SHA-256: 98b77fc41c08a4e2d6c9765bdb48ef850d1662dd63cbd67bd0a4b28b826afd2e.

---

<a id="pubmed-pmid-42800616-pegcetacoplan-v1"></a>

## Podocyte and tubular vacuolization in patients receiving pegcetacoplan.

> PubMed lists PMID 42800616 in Kidney international as Case Reports, Journal Article, with publication-date metadata of 2026-09-26 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42800616-pegcetacoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42800616-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-42800616-pegcetacoplan-v1
- Content SHA-256: `05a5345b678a7e35849bb7de626ef6c0edde0e554ddae12bca16ec7eae7f43c5`

### Claims and source pins

#### Headline

Podocyte and tubular vacuolization in patients receiving pegcetacoplan. ([`pubmed-observation-pmid-42800616-2026-10-16-81754f1888ef`](#source-pubmed-observation-pmid-42800616-2026-10-16-81754f1888ef))

#### Summary

PubMed lists PMID 42800616 in Kidney international as Case Reports, Journal Article, with publication-date metadata of 2026-09-26 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42800616-2026-10-16-81754f1888ef`](#source-pubmed-observation-pmid-42800616-2026-10-16-81754f1888ef))

#### Paragraph 1

PubMed lists PMID 42800616 in Kidney international as Case Reports, Journal Article, with publication-date metadata of 2026-09-26 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42800616-2026-10-16-81754f1888ef`](#source-pubmed-observation-pmid-42800616-2026-10-16-81754f1888ef))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42800616-2026-10-16-81754f1888ef`](#source-pubmed-observation-pmid-42800616-2026-10-16-81754f1888ef))

### Sources

<a id="source-pubmed-observation-pmid-42800616-2026-10-16-81754f1888ef"></a>
- **Podocyte and tubular vacuolization in patients receiving pegcetacoplan. · retained source version 1:2026-10-16:current:81754f1888ef14a3ae8ae9040243b5b855a4747c31f850d710b949bed418c25a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42800616/) (`pubmed-observation-pmid-42800616-2026-10-16-81754f1888ef`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Podocyte and tubular vacuolization in patients receiving pegcetacoplan." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-42800616-pegcetacoplan-v1 SHA-256: 05a5345b678a7e35849bb7de626ef6c0edde0e554ddae12bca16ec7eae7f43c5.

---

<a id="pubmed-pmid-42898424-pegcetacoplan-v1"></a>

## Distinct Pharmacodynamic Complement Biomarker Signatures Define Iptacopan and Pegcetacoplan Treatment in C3 Glomerulopathy.

> PubMed lists PMID 42898424 in Kidney international reports as Journal Article, with publication-date metadata of 2026-09-18 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42898424-pegcetacoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42898424-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-42898424-pegcetacoplan-v1
- Content SHA-256: `30ad962dd0a3209d532a28f4afc6f2041e81916bbe1b94aabee6cec378457f23`

### Claims and source pins

#### Headline

Distinct Pharmacodynamic Complement Biomarker Signatures Define Iptacopan and Pegcetacoplan Treatment in C3 Glomerulopathy. ([`pubmed-observation-pmid-42898424-2026-10-22-33f10dd31893`](#source-pubmed-observation-pmid-42898424-2026-10-22-33f10dd31893))

#### Summary

PubMed lists PMID 42898424 in Kidney international reports as Journal Article, with publication-date metadata of 2026-09-18 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42898424-2026-10-22-33f10dd31893`](#source-pubmed-observation-pmid-42898424-2026-10-22-33f10dd31893))

#### Paragraph 1

PubMed lists PMID 42898424 in Kidney international reports as Journal Article, with publication-date metadata of 2026-09-18 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42898424-2026-10-22-33f10dd31893`](#source-pubmed-observation-pmid-42898424-2026-10-22-33f10dd31893))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42898424-2026-10-22-33f10dd31893`](#source-pubmed-observation-pmid-42898424-2026-10-22-33f10dd31893))

### Sources

<a id="source-pubmed-observation-pmid-42898424-2026-10-22-33f10dd31893"></a>
- **Distinct Pharmacodynamic Complement Biomarker Signatures Define Iptacopan and Pegcetacoplan Treatment in C3 Glomerulopathy. · retained source version 1:2026-10-22:current:33f10dd31893e6f4da9e3bdd42077a84b0d371dfedf9d7e570841a62c1781650** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42898424/) (`pubmed-observation-pmid-42898424-2026-10-22-33f10dd31893`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Distinct Pharmacodynamic Complement Biomarker Signatures Define Iptacopan and Pegcetacoplan Treatment in C3 Glomerulopathy." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-42898424-pegcetacoplan-v1 SHA-256: 30ad962dd0a3209d532a28f4afc6f2041e81916bbe1b94aabee6cec378457f23.

---

<a id="pubmed-pmid-42930807-pegcetacoplan-v1"></a>

## Temporal, Phenotypic, and Treatment-Context Heterogeneity in Retinal Vasculitis Reporting with Pegcetacoplan: A United States Pharmacovigilance Study.

> PubMed lists PMID 42930807 in Journal of personalized medicine as Journal Article, with publication-date metadata of 2026-10-16 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42930807-pegcetacoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42930807-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-42930807-pegcetacoplan-v1
- Content SHA-256: `e89488e58df939eae451d4a893f000ef1efff4421c986a6876941a7bfefd5de8`

### Claims and source pins

#### Headline

Temporal, Phenotypic, and Treatment-Context Heterogeneity in Retinal Vasculitis Reporting with Pegcetacoplan: A United States Pharmacovigilance Study. ([`pubmed-observation-pmid-42930807-2026-10-28-bbfcd0d4ea6e`](#source-pubmed-observation-pmid-42930807-2026-10-28-bbfcd0d4ea6e))

#### Summary

PubMed lists PMID 42930807 in Journal of personalized medicine as Journal Article, with publication-date metadata of 2026-10-16 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42930807-2026-10-28-bbfcd0d4ea6e`](#source-pubmed-observation-pmid-42930807-2026-10-28-bbfcd0d4ea6e))

#### Paragraph 1

PubMed lists PMID 42930807 in Journal of personalized medicine as Journal Article, with publication-date metadata of 2026-10-16 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42930807-2026-10-28-bbfcd0d4ea6e`](#source-pubmed-observation-pmid-42930807-2026-10-28-bbfcd0d4ea6e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42930807-2026-10-28-bbfcd0d4ea6e`](#source-pubmed-observation-pmid-42930807-2026-10-28-bbfcd0d4ea6e))

### Sources

<a id="source-pubmed-observation-pmid-42930807-2026-10-28-bbfcd0d4ea6e"></a>
- **Temporal, Phenotypic, and Treatment-Context Heterogeneity in Retinal Vasculitis Reporting with Pegcetacoplan: A United States Pharmacovigilance Study. · retained source version 1:2026-10-28:current:bbfcd0d4ea6e89b1aabe7abd63027920d2792e3cd12f3d05bb1c6cf9ba29873e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42930807/) (`pubmed-observation-pmid-42930807-2026-10-28-bbfcd0d4ea6e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Temporal, Phenotypic, and Treatment-Context Heterogeneity in Retinal Vasculitis Reporting with Pegcetacoplan: A United States Pharmacovigilance Study." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-42930807-pegcetacoplan-v1 SHA-256: e89488e58df939eae451d4a893f000ef1efff4421c986a6876941a7bfefd5de8.

---

<a id="pubmed-pmid-42972953-pegcetacoplan-v1"></a>

## Mixed Intravascular and Extravascular Hemolysis Despite Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case of Switching to Pegcetacoplan.

> PubMed lists PMID 42972953 in Turkish journal of haematology : official journal of Turkish Society of Haematology as Journal Article, with publication-date metadata of 2026-11-03 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42972953-pegcetacoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42972953-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-42972953-pegcetacoplan-v1
- Content SHA-256: `25ae10a7d2c00af9f3ee526e572b1fa31adb0e95f060c0fd5427c67f5e03f8a2`

### Claims and source pins

#### Headline

Mixed Intravascular and Extravascular Hemolysis Despite Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case of Switching to Pegcetacoplan. ([`pubmed-observation-pmid-42972953-2026-11-03-f9453a6cce03`](#source-pubmed-observation-pmid-42972953-2026-11-03-f9453a6cce03))

#### Summary

PubMed lists PMID 42972953 in Turkish journal of haematology : official journal of Turkish Society of Haematology as Journal Article, with publication-date metadata of 2026-11-03 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42972953-2026-11-03-f9453a6cce03`](#source-pubmed-observation-pmid-42972953-2026-11-03-f9453a6cce03))

#### Paragraph 1

PubMed lists PMID 42972953 in Turkish journal of haematology : official journal of Turkish Society of Haematology as Journal Article, with publication-date metadata of 2026-11-03 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42972953-2026-11-03-f9453a6cce03`](#source-pubmed-observation-pmid-42972953-2026-11-03-f9453a6cce03))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42972953-2026-11-03-f9453a6cce03`](#source-pubmed-observation-pmid-42972953-2026-11-03-f9453a6cce03))

### Sources

<a id="source-pubmed-observation-pmid-42972953-2026-11-03-f9453a6cce03"></a>
- **Mixed Intravascular and Extravascular Hemolysis Despite Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case of Switching to Pegcetacoplan. · retained source version 1:2026-11-03:current:f9453a6cce034dc6b5015494c99c937e5197aee5798feb19ed5565a06ca07b52** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42972953/) (`pubmed-observation-pmid-42972953-2026-11-03-f9453a6cce03`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Mixed Intravascular and Extravascular Hemolysis Despite Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case of Switching to Pegcetacoplan." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-42972953-pegcetacoplan-v1 SHA-256: 25ae10a7d2c00af9f3ee526e572b1fa31adb0e95f060c0fd5427c67f5e03f8a2.

---

<a id="pubmed-pmid-42998772-pegcetacoplan-v1"></a>

## Pegcetacoplan for geographic atrophy: Bridging the "clinical relevance gap" through precision medicine.

> PubMed lists PMID 42998772 in Survey of ophthalmology as Journal Article, Review, with publication-date metadata of 2026-11-07 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42998772-pegcetacoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42998772-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-42998772-pegcetacoplan-v1
- Content SHA-256: `057551f8efc41838468ca047efade7d65639a22d64b8a0470e732f664ee95d4f`

### Claims and source pins

#### Headline

Pegcetacoplan for geographic atrophy: Bridging the "clinical relevance gap" through precision medicine. ([`pubmed-observation-pmid-42998772-2026-11-10-bc9b0ed7e9c0`](#source-pubmed-observation-pmid-42998772-2026-11-10-bc9b0ed7e9c0))

#### Summary

PubMed lists PMID 42998772 in Survey of ophthalmology as Journal Article, Review, with publication-date metadata of 2026-11-07 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42998772-2026-11-10-bc9b0ed7e9c0`](#source-pubmed-observation-pmid-42998772-2026-11-10-bc9b0ed7e9c0))

#### Paragraph 1

PubMed lists PMID 42998772 in Survey of ophthalmology as Journal Article, Review, with publication-date metadata of 2026-11-07 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42998772-2026-11-10-bc9b0ed7e9c0`](#source-pubmed-observation-pmid-42998772-2026-11-10-bc9b0ed7e9c0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42998772-2026-11-10-bc9b0ed7e9c0`](#source-pubmed-observation-pmid-42998772-2026-11-10-bc9b0ed7e9c0))

### Sources

<a id="source-pubmed-observation-pmid-42998772-2026-11-10-bc9b0ed7e9c0"></a>
- **Pegcetacoplan for geographic atrophy: Bridging the "clinical relevance gap" through precision medicine. · retained source version 1:2026-11-10:current:bc9b0ed7e9c0235d800a6f9886c8d2beda221641379cda9333f91776195d1789** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42998772/) (`pubmed-observation-pmid-42998772-2026-11-10-bc9b0ed7e9c0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pegcetacoplan for geographic atrophy: Bridging the 'clinical relevance gap' through precision medicine." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-42998772-pegcetacoplan-v1 SHA-256: 057551f8efc41838468ca047efade7d65639a22d64b8a0470e732f664ee95d4f.

---

<a id="pubmed-pmid-43024395-pegcetacoplan-v1"></a>

## Pegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN.

> PubMed lists PMID 43024395 in Journal of the American Society of Nephrology : JASN as Journal Article, with publication-date metadata of 2026-11-13 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-43024395-pegcetacoplan:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-43024395-pegcetacoplan/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-43024395-pegcetacoplan-v1
- Content SHA-256: `a97731afc946cd67481f7cba3ebc622be4c42746f56c8b7f5f2ccd9a689dcc74`

### Claims and source pins

#### Headline

Pegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN. ([`pubmed-observation-pmid-43024395-2026-11-13-692fb936290a`](#source-pubmed-observation-pmid-43024395-2026-11-13-692fb936290a))

#### Summary

PubMed lists PMID 43024395 in Journal of the American Society of Nephrology : JASN as Journal Article, with publication-date metadata of 2026-11-13 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-43024395-2026-11-13-692fb936290a`](#source-pubmed-observation-pmid-43024395-2026-11-13-692fb936290a))

#### Paragraph 1

PubMed lists PMID 43024395 in Journal of the American Society of Nephrology : JASN as Journal Article, with publication-date metadata of 2026-11-13 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-43024395-2026-11-13-692fb936290a`](#source-pubmed-observation-pmid-43024395-2026-11-13-692fb936290a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-43024395-2026-11-13-692fb936290a`](#source-pubmed-observation-pmid-43024395-2026-11-13-692fb936290a))

### Sources

<a id="source-pubmed-observation-pmid-43024395-2026-11-13-692fb936290a"></a>
- **Pegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN. · retained source version 1:2026-11-13:current:692fb936290af8e9d3d03db369a047edaf19c0e6daf93d79cadeeb83737a9857** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/43024395/) (`pubmed-observation-pmid-43024395-2026-11-13-692fb936290a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/pegcetacoplan.json#pubmed-pmid-43024395-pegcetacoplan-v1 SHA-256: a97731afc946cd67481f7cba3ebc622be4c42746f56c8b7f5f2ccd9a689dcc74.

